Australian study tallies cost of genetic eye disease at $5.2 million per patient

Article

Researchers totaled the societal and healthcare costs of inherited retinal diseases.

A woman wearing glasses buys medicine from a pharmacy. Image credit: ©gpointstudio – stock.adobe.com

Lifetime individual costs for those with IRDs total around $5.2 million, according to a new study. Image credit: ©gpointstudio – stock.adobe.com

Inherited retinal diseases (IRDs) cost individuals millions of dollars, and present an enormous national cost as well, according to a study conducted in Australia.1 Researchers quantified household and lifetime cost, with distinctions between categories such as healthcare costs and societal costs, such as government services and income loss. The results of the microsimulation modeling study were published in The Medical Journal of Australia. Authors included Deborah Schofield, Joshua Kraindler, Owen Tan, Natalie Hart, Rupendra N Shrestha, and Sarah West, all associated with GenIMPACT: Centre for Economic Impacts of Genomic Medicine, at Macquarie University, Sydney; and Liny Tan, Alan Ma, John R Grigg, and Robyn V Jamieson, of the Children's Medical Research Institute, University of Sydney.

Measures included annual and lifetime costs for people with IRDs, collected in interviews of patients, their carers, and their spouses. On average, the total estimated lifetime cost of IRDs was $5.2 million per person. Societal costs far outweighed the health care costs of IRDs. As categorized by the researchers, 87 percent of all costs were societal. Lifetime health care costs only totaled 13% of the per-person amount.1

Itemized results found the highest cost came from lost income for people with IRDs. The lifetime cost of lost wages was estimated at $1.4 million. At a close second was lost income for carers and spouses, which totaled a lifetime average of $1.1 million. Lifetime social support spending by the Australian government, excluding costs from National Disability Insurance Scheme (NDIS), totaled $1 million.1

Annual costs were twice as high for people who were legally blind as for those with less impaired vision,1 with blind participants totaling an annual cost of $83,910 vs $41,357 per less-impaired person. The study's authors recorded the mean age of participants as 42.1 years old, and confirmed no participants were over 80 years of age.

In addition, the authors acknowledged the financial impact of vision loss extends beyond patients with IRDs. Reduced quality of life and economic impact is also carried by family members, especially those who serve as full-time or even informal caretakers. As such, researchers calculated the per-household cost of IRDs; that figure was an estimated lifetime total of $5.6 million per household.1

The estimated total annual cost of IRDs in Australia was $830 million to $1.66 billion. The microsimulation modelling approach was used to provide a more accurate and precise reflection of income and tax factors. Healthcare costs did not include NDIS costs. Out-of-pocket health costs reflected only a small percentage of healthcare expenses – due, the study's authors said, to a lack of treatment options for IRDs.1 Rather, healthcare costs were largely comprised of housing modifications, transport modifications, and other healthcare expenses. The additional health costs may have been paid out-of-pocket because patients were not aware those health supports were available, or when and where access to social services was limited.

Reference.
1. Schofield, D., Kraindler, J., et al. The health care and societal costs of inherited retinal diseases in Australia: a microsimulation modelling study. Med J Aust. Published June 10, 2023. Accessed June 21, 2023. https://doi.org/10.5694/mja2.51997

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.